LAVEROCK THERAPEUTICS LIMITED

Active Chandler's Ford

Research and experimental development on biotechnology

29 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
L

LAVEROCK THERAPEUTICS LIMITED

Research and experimental development on biotechnology

Founded 13 Jul 2021 Active Chandler's Ford, United Kingdom 29 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology

Previous Company Names

SKYLARK THERAPEUTICS LIMITED 13 Jul 2021 — 22 Aug 2022
Accounts Submitted 20 May 2026 Next due 30 Sept 2026 3 months remaining
Confirmation Submitted 17 Jul 2025 Next due 26 Jul 2026 1 month remaining
Net assets £5M £4M 2024 year on year
Total assets £6M £4M 2024 year on year
Total Liabilities £922K £74K 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

C/O Xeinadin First Floor Secure House Lulworth Close Chandler's Ford SO53 3TL United Kingdom

Telephone

0800 000 0000

Website

www.example.com

Full company profile for LAVEROCK THERAPEUTICS LIMITED (13508159), an active life sciences and medical technology company based in Chandler's Ford, United Kingdom. Incorporated 13 Jul 2021. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type small
Next accounts 31 Dec 2025
Due by 30 Sept 2026 3 months remaining

Net Assets, Total Assets & Total Liabilities (2022–2024)

Cash in Bank

£3.46M

Decreased by £5.35M (-61%)

Net Assets

£5.03M

Decreased by £4.20M (-46%)

Total Liabilities

£921.87k

Decreased by £73.63k (-7%)

Turnover

N/A

Employees

29

Increased by 14 (+93%)

Debt Ratio

15%

Increased by 5 (+50%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
31 Dec Year End
2023
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 2

Investors (7)

Investor NameInvestor SinceParticipating Rounds
Investor 3Sept 2023Seed
Investor 4Sept 2023Seed
Investor 5Sept 2023Seed

Share Capital

Share Capital

Share allotments and capital structure

13 Allotments 2,631,303 Shares £7.08m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
21 Jul 20253,361£33.61£0.01
27 Jun 2025257,288£828k£3.22
5 Jun 2025155,280£458k£2.952
5 Jun 2025155,280£42k£0.268
5 Jun 2025209,627£675k£3.22

Officers

Officers

1 active 2 resigned
Status
John Robert BrownDirectorBritishUnited Kingdom712 Feb 2022Active

Shareholders

Shareholders (152)

Calculus Nominees Limited
10.2%
891,961
Calculus Nominees Limited
10.0%
875,700

Persons with Significant Control

Persons with Significant Control (0)

0 Active 1 Ceased

Tropic Biosciences Uk Limited

Ceased 29 Sept 2023

Ceased

Group Structure

Group Structure

No group structure identified

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
20 May 2026AccountsAnnual accounts made up to 31 Dec 2025
13 May 2026OfficersTermination of Sarah Noonberg as director on 1 Sept 2025
21 Jul 2025CapitalAllotment of shares (GBP 87,857.63) on 21 Jul 2025
17 Jul 2025Confirmation StatementConfirmation statement made on 12 Jul 2025 with updates
9 Jul 2025CapitalAllotment of shares (GBP 87,824.02) on 27 Jun 2025
20 May 2026 Accounts

Annual accounts made up to 31 Dec 2025

13 May 2026 Officers

Termination of Sarah Noonberg as director on 1 Sept 2025

21 Jul 2025 Capital

Allotment of shares (GBP 87,857.63) on 21 Jul 2025

17 Jul 2025 Confirmation Statement

Confirmation statement made on 12 Jul 2025 with updates

9 Jul 2025 Capital

Allotment of shares (GBP 87,824.02) on 27 Jun 2025

Recent Activity

Latest Activity

Annual accounts made up to 31 Dec 2025

3 weeks ago on 20 May 2026

Termination of Sarah Noonberg as director on 1 Sept 2025

4 weeks ago on 13 May 2026

Allotment of shares (GBP 87,857.63) on 21 Jul 2025

10 months ago on 21 Jul 2025

Confirmation statement made on 12 Jul 2025 with updates

10 months ago on 17 Jul 2025

Allotment of shares (GBP 87,824.02) on 27 Jun 2025

11 months ago on 9 Jul 2025